Investors Contact Payment Careers Research Request Physician Portal
Interpace Biosciences®, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Diagnostics
  • Pharma Solutions
  • Support
  • Lab
  • News & Media
    • Press Releases
    • In The News
    • Presentations
    • Events
  • Investors
  • Contact
  • Payment
  • Careers
  • Research Request
  • Physician Portal

Press Releases

News & Media

News & Media

  • Press Releases
  • In The News
  • Presentations
  • Events

Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results

Aug 9, 2023

Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement

Jul 10, 2023

Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023

Jun 5, 2023

Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results

May 12, 2023

Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results

Mar 27, 2023

Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern

Nov 14, 2022

Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting

Oct 20, 2022

Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved

Sep 1, 2022

Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.

Aug 31, 2022

Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved

Aug 15, 2022
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...23
© 2023 Interpace Biosciences®, Inc. All Rights Reserved.
Privacy Policy HIPAA Privacy Disclaimer Sitemap Manage Cookie Preferences
We Own Our Future Logo
  • Linkedin